Hypercalcaemia in patients with breast cancer: Patterns and treatment outcomes among in-patients in a Malaysian tertiary healthcare facility
Purpose: To assess the patterns of use of bisphosphonate therapies for hypercalcaemia in breast cancer patients, and their outcomes.
Methods: A retrospective chart review study of breast cancer patients hospitalised between 2009 and 2014 at Penang Hospital, a public tertiary hospital in Malaysia was conducted. Patients with mild (total serum calcium = 10.5 - 11.9 mg/dl); moderate (12 - 12.9 mg/dl), and severe (≥13 mg/dl) hypercalcaemia at cancer diagnosis or during cancer treatment were included. Relevant data were extracted from medical records analyzed statistically.
Results: From the records, 1,023 breast cancer patients were identified, 164 of which had hypercalcaemia at cancer diagnosis or during cancer treatment. About 25 % of the hypercalcaemic patients had advanced-stage cancer, while 20 % had severe hypercalcaemia. Regarding the pattern of bisphosphonate use, the results showed that more than half of the patients received pamidronate as first-line treatment; about a quarter were treated with zoledronic acid, while others received only normal saline. These treatments produced significant reductions in serum calcium levels relative to baseline values.
Conclusion: Although zoledronic acid is considered as the treatment of choice for hypercalcemia of malignancy, the current study found that the first line treatment used for hypercalcemia is pamidronate, mainly because its cost is lower than that of zoledronic acid.
Keywords: Pamidronate, Zoledronic acid, Bisphosphonates, Calcium levels
Submission of a manuscript to this journal is a representation that the manuscript has not been published previously and is not under consideration for publication elsewhere.
All authors named in each manuscript would be required to sign a form (to be supplied by the Editor) so that they may retain their copyright in the article but to assign to us (the Publishers) and its licensees in perpetuity, in all forms, formats and media (whether known or created in the future) to (i) publish, reproduce, distribute, display and store the contribution, (ii) translate the contribution into other languages, create adaptations, reprints, include within collections and create summaries, extracts and/or abstracts of the contribution, (iii) create any other derivative works(s) based on the contribution, (iv) to exploit all subsidiary rights in the contribution, (v) the inclusion of electronic links from the contribution to third party material where-ever it may be located, and (vi) license any thrid party to do any or all of the above.